Epidemiology and Mechanisms of Ceftazidime-Avibactam Resistance in Gram-Negative Bacteria

Xu，Tingting1; Guo，Yuqi1; Ji，Yang1; Wang，Baohong2; Zhou，Kai1

2022-04-01

10.1016/j.eng.2020.11.004

Engineering   影响因子和分区

2095-8099

2096-0026

Carbapenem resistance presents a major challenge for the global public health network, as clinical infections caused by carbapenem-resistant organisms (CRO) are frequently associated with significant morbidity and mortality. Ceftazidime-avibactam (CAZ-AVI) is a novel cephalosporin/beta-lactamase inhibitor combination offering an important advance in the treatment of CRO infections. CAZ-AVI has been reported to inhibit the activities of Ambler classes A, C, and some class D enzymes. However, bacterial resistance has been emerging shortly after the introduction of this combination in clinical use, with an increasing trend. Understanding these resistance mechanisms is crucial for guiding the development of novel treatments and aiding in the prediction of underlying resistance mechanisms. This review aims to systematically summarize the epidemiology of CAZ-AVI-resistant strains and recently identified resistance mechanisms of CAZ-AVI, with a focus on the production of beta-lactamase variants, the hyperexpression of beta-lactamases, reduced permeability, and overexpressed efflux pumps. The various mechanisms of CAZ-AVI resistance that have emerged within a short timescale emphasize the need to optimize the use of current agents, as well as the necessity for the surveillance of CAZ-AVI-resistant pathogens. (C) 2021 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.

Ceftazidime-avibactam Resistance mechanism Carbapenem-resistant beta-lactam/beta-lactamase inhibitor

SCI ; EI

英语

第一

National Key Research and Development Program of China[2017YFC1200200] ; Major Infectious Diseases such as AIDS and Viral Hepatitis Prevention and Control Technology Major Projects[2018ZX10712-001] ; National Natural Science Foundation of China["81702045","81902030"] ; Shenzhen Basic Research projects[JCYJ20190807144409307]

Engineering

Engineering, Multidisciplinary

WOS:000824524600019

ELSEVIER

2-s2.0-85113146526

Web of Science

1.Shenzhen Institute of Respiratory Diseases,Shenzhen People's Hospital & 2nd Clinical Medical College of Jinan University & 1st Affiliated Hospital of Southern University of Science and Technology,Shenzhen,518020,China
2.State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou,310003,China

Xu，Tingting,Guo，Yuqi,Ji，Yang,et al. Epidemiology and Mechanisms of Ceftazidime-Avibactam Resistance in Gram-Negative Bacteria[J]. Engineering,2022,11.

Xu，Tingting,Guo，Yuqi,Ji，Yang,Wang，Baohong,&Zhou，Kai.(2022).Epidemiology and Mechanisms of Ceftazidime-Avibactam Resistance in Gram-Negative Bacteria.Engineering,11.

Xu，Tingting,et al."Epidemiology and Mechanisms of Ceftazidime-Avibactam Resistance in Gram-Negative Bacteria".Engineering 11(2022).